Midazolam FrostPharma (midazolam) nasal spray now in stock in Finland

Helsinki, 05.11.2026 – Midazolam FrostPharma nasal spray is an approved medicine in the Nordic countries and is now available with good stock levels in Finland. The Midazolam FrostPharma nasal spray is intended for the emergency treatment of prolonged convulsive epileptic seizures. The nasal spray is also indicated for conscious sedation before and during diagnostic or therapeutic procedures, with or without local anaesthesia, and as premedication before induction of anaesthesia.

“When a prolonged acute convulsive seizure occurs, rapid and practical drug administration is crucial. Effective treatment of prolonged convulsive seizures requires a treatment that is easy to administer. Intranasal administration is a well-established and effective approach for acute seizures, making midazolam nasal spray a valuable treatment option for both paediatric and adult patients”, says Associate Professor Leena Kämppi, specialist in neurology at Epilepsia Helsinki in Helsinki University Hospital (HUS) and University of Helsinki.

Now in stock

Midazolam FrostPharma nasal spray is now available in Finland with good stock levels. The medicine is intended for the treatment of prolonged, acute, convulsive epileptic seizures.¹

About prolonged convulsive epileptic seizures

Prolonged (generalised) convulsive seizures are clinically defined as seizures lasting longer than 2 minutes, or repeated seizures without the patient returning to their baseline state between seizures.² The condition is time-critical and carries a risk of hypoxaemia, cardiorespiratory compromise and progression to status epilepticus if the seizure continues beyond 5 minutes.³ An estimated 30 percent of patients with epilepsy do not achieve seizure freedom with preventive medication and may therefore need emergency treatment.⁴

About Midazolam FrostPharma

Midazolam FrostPharma is a nasal spray containing midazolam at a concentration of 50 mg/ml in single-dose containers. It is available in strengths of 2.5 mg, 3.75 mg and 5 mg. The nasal spray is indicated for the treatment of prolonged, acute convulsive seizures, for conscious sedation before and during diagnostic or therapeutic procedures, with or without local anaesthesia, and as premedication before induction of anaesthesia. For conscious sedation and premedication, the medicine may only be administered by healthcare professionals. Parents or caregivers may only administer the medicine to patients with diagnosed epilepsy. Midazolam FrostPharma is intended for adults and children aged 2 years and older with a body weight greater than or equal to 12 kg.¹ The medicine is absorbed rapidly through the nasal mucosa, and the maximum blood concentration is reached after an average of 14 minutes.^1,5 The nasal spray can be administered regardless of the patient's position and does not require established intravenous access. In the ARTEMIS-1 study, treatment success was achieved in 53.7 percent with intranasal midazolam compared with 34.4 percent with placebo.⁶Commonly reported adverse reactions include local nasal irritation or discomfort, drowsiness and headache.^1,6

ID 16741745 11/26 Press release Midazolam FrostPharma FI

FrostPharma – A fast-growing pharmaceutical company with European reach and Nordic roots

With a strong commitment to improving patient care, FrostPharma identifies, develops and commercialises medicines that create added value. With a base in the Nordics and a growing presence in selected European markets, we combine local market knowledge with all the capabilities needed to make meaningful treatments available to patients and healthcare providers.

Through focused product development, strategic partnerships and a gradually expanding geographic presence, FrostPharma is building a European platform for sustainable growth. Our development so far has been driven by an experienced and dedicated team, and we are convinced that the same entrepreneurial spirit and drive will carry FrostPharma into the next phase of our European expansion.

Rebecka Grund, Head of Marketing Center
📧 rebecka.grund@frostpharma.com

🌐 www.frostpharma.se
📍 Berga Backe 2, 182 53 Danderyd, Sweden
📞 +46 (0) 8 24 36 60

References

1. Summary of Product Characteristics for nasal spray, solution in single-dose container, 2.5 mg, 3.75 mg and 5 mg. Sections 2, 4.1, 4.2, 4.8 and 5.2.

2. Finnish Medical Society Duodecim. Current Care Guidelines: Pitkittynyt epileptinen kohtaus ja status epilepticus. Published 6 February 2026. https://www.kaypahoito.fi/hoi50030. Accessed 30 October 2026.

3. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus: report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515–1523. doi:10.1111/epi.13121.

4. Ugeskrift for Læger. Epilepsy. 2014. ugeskriftet.dk/videnskab/epilepsi

5. European Medicines Agency (EMA). Nasolam and associated names: Article 29(4) referral – public assessment report.EMA/190723/2022.

6. Detyniecki K, Van Ess PJ, Sequeira DJ, et al. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters—a randomized, double-blind, placebo-controlled trial. Epilepsia.2019;60:1797–1808. doi:10.1111/epi.15159.